Zaprinast increases cyclic GMP levels in plasma and in aortic tissue of rats
| Autor: | Lynn T. Wheeler, Donald C. Bode, R. Allan Buchholz, Ronald L. Dundore, Peter G. Habeeb, Dawn M. Clas, Paul J. Silver, Edward D. Pagani |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Male
medicine.medical_specialty Purinones Radioimmunoassay Blood Pressure chemistry.chemical_compound 3' 5'-Cyclic-GMP Phosphodiesterases Internal medicine medicine.artery Rats Inbred SHR Blood plasma medicine Animals Aorta Abdominal Phosphodiesterase inhibitor Cyclic GMP Pharmacology Aorta Analysis of Variance biology Dose-Response Relationship Drug business.industry Phosphodiesterase Rats Endocrinology Blood pressure medicine.anatomical_structure chemistry Enzyme inhibitor Hypertension Injections Intravenous biology.protein business Zaprinast Blood vessel |
| Zdroj: | European journal of pharmacology. 249(3) |
| ISSN: | 0014-2999 |
| Popis: | The purpose of this study was to determine if significant relationships exist between plasma and aortic cyclic GMP (cGMP) levels and pharmacodynamic effect after the i.v. administration of the cGMP-selective phosphodiesterase inhibitor zaprinast to conscious, spontaneously hypertensive rats. Zaprinast dose-dependently increased plasma and aortic cGMP levels at 10, 18 and 30 mg/kg and decreased mean arterial blood pressure (MAP) at 18 and 30 mg/kg. The concentrations of cGMP in the plasma and in the aorta were significantly correlated (r = 0.765, P0.0001). The changes in MAP were significantly correlated to aortic (r = -0.750, P0.0001) and plasma (r = -0.762, P0.0001) cGMP levels. We conclude that plasma cGMP may be an index of cGMP-selective phosphodiesterase inhibition in vivo. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|